Lantheus announced the closing of the strategic collaboration agreements previously announced on November 14, 2022 between Lantheus and POINT Biopharma Global (PNT). Closing of the agreements was subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LNTH:
- Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
- Lantheus grants rights for use of microbubbles to SonoThera
- Lantheus announces pricing of offering of $500M convertible senior notes
- Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
- Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
